Showing 1881-1890 of 2123 results for "".
- New Nasal Spray Treatment for Migraine Approvedhttps://practicalneurology.com/news/new-nasal-spray-treatment-for-migraine-approved/2470137/The Food and Drug Administration (FDA) approved a new nasal spray for the treatment of acute migraine with or without aura in adults. Zavegepant (Zavzpret; Pfizer, New York, NY) represents the first intranasal-administered
- Next Generation DHODH Inhibitor Helps Delay Disability in Those with Relapsing-Remitting MShttps://practicalneurology.com/news/next-generation-dhodh-inhibitor-helps-delay-disability-in-those-with-relapsing-remitting-ms/2470124/New clinical trial data suggest that vidofludimus calcium therapy (VidoCa; Immunic, New York, NY) for r
- Antidepressants Safe in Those Taking Ozanimod for Relapsing MShttps://practicalneurology.com/news/antidepressants-safe-in-those-taking-ozanimod-for-relapsing-ms/2470123/Data presented at the Americas Committee for Treatment & Research in Multiple Sclerosis (ACTRIMS) Forum 2023 suggest that concurrent administration of ozanimod (Zeposia; Bristol Myers Squibb, New York, NY) with selectiv
- Ozanimod Comparable to Diroximel Fumarate for Relapsing-Remitting MShttps://practicalneurology.com/news/ozanimod-comparable-to-diroximel-fumarate-for-relapsing-remitting-ms/2470121/According to results from a matching-adjusted indirect comparison study, ozanimod (Zeposia; Bristol Myers Squibb, New York, NY) had
- Reboxetine Helpful in Obstructive Sleep Apnea Treatmenthttps://practicalneurology.com/news/reboxetine-helpful-in-obstructive-sleep-apnea-treatment/2470118/According to results presented in the Journal of Clinical Sleep Medicine, treatment of obstructive sleep apnea (OSA) with reboxetine (Edronax; Pfizer, New York, NY) was effective at reducing OSA symptom severity. Res
- FDA Approves Monoclonal Antibody for Treating Relapsing MShttps://practicalneurology.com/news/fda-approves-monoclonal-antibody-for-treating-relapsing-ms/2470088/The Food and Drug Administration (FDA) approved ublituximab (Briumvi; TG Therapeutics, New York, NY) for treating relapsing forms of multiple sclerosis (MS) in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
- Cenobamate Reduces Antiseizure Medication Use in Adults With Focal Onset Seizureshttps://practicalneurology.com/news/cenobamate-reduces-antiseizure-medication-use-in-adults-with-focal-onset-seizures/2470080/Adults with focal onset seizures (also known as partial seizures) treated with cenobamate (Xcopri, SK Life Science, Paramus, NJ) experienced a 29% reduction in concomitant antiseizure medication use after 1 year and a 32% reduction after 2 years, according to research presented at the American Ep
- FDA Issues Refusal To File Letter for New Biologics License Application for Stem Cell ALS Treatmenthttps://practicalneurology.com/news/fda-does-not-file-new-biologics-license-application-for-stem-cell-amyotrophic-lateral-sclerosis-treatment/2470068/The Food and Drug Administration (FDA) has issued a refusal to file letter for the Biologics License Application (BLA) for autologous neurotrophic factor-secreting mesenchymal stem cells (MSC-NTF)(NurOwn; BrainStorm Cell Therapeutics, New York, NY) as treatment of amyotrophic lateral sclerosis (A
- First Participant in Phase 2/3 study of Trehalose Injection in Spinocerebellar Ataxiahttps://practicalneurology.com/news/first-participant-in-phase-23-study-of-trehalose-injection-in-spinocerebellar-ataxia/2470055/In the STRIDES study (NCT05490563), the first participant received a dose of 90.5 mg/mL trehalose injection (SLS-005; Seelos Therapeutics, New York, NY) for the treatment of type 3 spinocerebellar
- Neurotrophic Factor-Secreting Stem Cell Treatment Improves Function in Progressive Multiple Sclerosishttps://practicalneurology.com/news/neurotrophic-factor-secreting-stem-cell-treatment-improves-function-in-progressive-multiple-sclerosis/2470024/As published in Multiple Sclerosis, off-the-shelf growth factor-secreting stem cell (MSC-NTF) (NurOwn; BrainStorm Cell Therapeutics, New York, NY) treatment of people with progressive multiple sclerosis (MS) im